Shares of Septerna, Inc. (SEPN) have gained 57.8% over the past four weeks to close the last trading session at $9.42, but ...

Novo Nordisk is teaming up with Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

The developer of Wegovy will pay Septerna some $200 million in upfront and near-term fees to collaborate on small molecule medicines for weight loss. Novo is racing against rival Eli Lilly to develop ...

Investing.com -- Shares of Septerna, Inc. (Nasdaq:SEPN) surged 60% following the announcement of an exclusive global collaboration and license agreement with Novo Nordisk (NYSE:NVO) to develop oral ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

It’s understood the group has held talks with regulators about an Irish launch of its retail bank Marcus, a move that could ...